Acquiring Company
Fulcrum Therapeutics
Acquired Company
Slate Medicines
CambridgeRaleighBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaBiotechnologyHealth CareDescription
Fulcrum Therapeutics has agreed to merge with Slate Medicines in a stock-for-stock transaction, supported by a $245 million financing. Following the merger, pre-merger Slate holders will own approximately 55.9% of the combined entity. The merger aims to unite platforms and secure growth for the newly formed company.
Quick answer
Fulcrum Therapeutics is acquiring Slate Medicines, announced August 17, 2026. Fulcrum Therapeutics is based in Cambridge, Massachusetts, United States.
- How much did Fulcrum Therapeutics pay for Slate Medicines?
- The deal value was not disclosed.
- What does Fulcrum Therapeutics do?
- Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases.
- Where are Fulcrum Therapeutics and Slate Medicines based?
- Fulcrum Therapeutics is based in Cambridge, Massachusetts, United States. Slate Medicines is based in Raleigh, North Carolina, United States.
- Who are the decision-makers at Fulcrum Therapeutics?
- Fundz holds 1 contact at Fulcrum Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Therapeutics and Pharmaceutical
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Tarsus Pharmaceuticals to acquire Alkeus Pharmaceuticals (August 6, 2026)
- Tarsus acquires iRenix Medical for IRX-101 development (July 8, 2026)
- Aurinia completes acquisition of Kezar Life Sciences (August 29, 2026)
- Bristol-Myers acquires Medarex for cancer pipeline (August 2, 2026)
- Jazz Pharmaceuticals acquires Actio Biosciences (August 10, 2026)
- Supernus to merge with Indivior Pharmaceuticals (August 3, 2026)
Who to call at Fulcrum Therapeutics, and when
When Fulcrum Therapeutics changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Fulcrum Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Fulcrum Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Fulcrum Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Fulcrum Therapeutics makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Slate Medicines?
Slate Medicines was acquired by Fulcrum Therapeutics, based in Cambridge. The deal was reported on August 17, 2026. Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases. Fulcrum Therapeutics is publicly traded (FULC) and operates in Biotechnology.
When did Fulcrum Therapeutics acquire Slate Medicines?
Fulcrum Therapeutics's acquisition of Slate Medicines was reported on August 17, 2026. Fulcrum Therapeutics has agreed to merge with Slate Medicines in a stock-for-stock transaction, supported by a $245 million financing. Following the merger, pre-merger Slate holders will own approximately 55.9% of the combined entity. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Slate Medicines do?
Slate Medicines, Inc. is a biotech company focused on advancing next generation therapeutics for migraine and other headache disorders. It is privately held, operating in Biotechnology, and is based in Raleigh.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.